Navigation Links
Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
Date:12/19/2011

>

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the pr
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
2. alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
3. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
4. Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography
5. 23andMe Announces Breast Cancer Initiative
6. Amoena Helps Women Re-shape Their Lives After Breast Cancer Surgery
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
9. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
10. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
11. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... Oct. 27, 2014 Pressure BioSciences, Inc. ... leader in the development and sale of high ... research market, today announced that Professor Ruedi ... accurate, highly reproducible, and robust method to allow ... protein analysis on small needle biopsy samples by ...
(Date:10/26/2014)... October 26, 2014 The report ... ADC, Network Security Equipment, WAN Optimization Appliances]: Global ... segments the data center networking market into various ... revenues. The report also identifies the factors driving ... impacting it along with the future roadmaps. , ...
(Date:10/25/2014)... 2014 ViaDerma, Inc ... devoted to bringing new products to market, is ... ViaDerma has developed an innovative, patent-pending dual carrier ... transfer of pharmaceutical active ingredients to penetrate the ... localized therapy. The transdermal delivery method also overcomes ...
(Date:10/25/2014)... October 24, 2014 DuPont Pioneer ... to more than double the acreage contracted for ... supplying its soybean crush facility in Salisbury, Md. ... program will target several markets including foodservice and ... good performance. , For the 2015 growing season, ...
Breaking Biology Technology:Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4
... Calif., July 26, 2011 Synterra Energy, Inc. ... and assets for waste biomass conversion from Pacific ... Lion Bio-Energy (Toledo, Ohio).  With the merger, Synterra ... bio-refineries for the economic production of renewable fuels, ...
... 26, 2011   At the ... Center for Devices and Radiologic Health of the United States ... Thursday July 21 in Gaithersburg, Maryland to review the results ... charge of the panel was to review the clinical data ...
... Neogen Corporation (NASDAQ: NEOG ) announced today that ... 31, increased 30% from the previous year to $22,839,000. Net ... compared to the prior year,s $0.76 per share. ... up from $140,509,000 in the company,s previous fiscal year. Both ...
Cached Biology Technology:Synterra Energy Merges Key Technologies to Commercialize Next Generation Integrated Bio-refinery 2FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States 2FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States 3FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States 4Neogen Reports 30% Increase in Net Income 2Neogen Reports 30% Increase in Net Income 3Neogen Reports 30% Increase in Net Income 4Neogen Reports 30% Increase in Net Income 5
(Date:10/29/2014)... decompose, their types and numbers of bugs and ... mean the difference between a closed case and ... using a more than $866,000 U.S. Department of ... these changing populations. The microbial communities may provide ... gender, race, socioeconomic relations and more, said Eric ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... Ghrelin is a hormone released by the stomach and ... viewed as a psychoactive substance that primarily affects brain ... , This knowledge, combined with findings from animal ... the potential to stimulate alcohol craving. , Dr. Lorenzo ... found that, as they had anticipated, alcohol craving was ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... CA) Researchers at the Burnham Institute for Medical Research ... intestinal protein leakage in mice, allowing the team to ... in an in vivo setting. Protein-losing enteropathy (PLE) encompasses ... into the digestive tract. One type of PLE ...
... the Hinode mission have shed new light on the Sun,s ... disrupt power grids, satellites and communications on Earth. The ... journal Science. , Data from Hinode, a Japanese (JAXA) mission ... role in driving the solar wind into space. The solar ...
... new and compelling argument for reducing fish harvests the ... short-term pain of lower catches for the long-term gain of ... ground-breaking study on fisheries over-exploitation. They say their findings, ... a key cause of over-fishing industry opposition to lower ...
Cached Biology News:Safe and effective therapy discovered for patients with protein-losing enteropathy 2Hinode: new insights on the origin of solar wind 2Economists: Reduce fish catch now for bigger net profits later 2Economists: Reduce fish catch now for bigger net profits later 3
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
... Type Liquid. In 100 mM KCl, ... EDTA, 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. ... monomeric protein of 765 amino acids encoded by ... both positive and negative supercoiled DNAs without the ...
Request Info...
... III digests duplex DNA in a 3'-> ... or nick, producing stretches of single-stranded DNA. ... Exonuclease III proceeds at a uniform rate ... rate of exonucleolytic excision of deoxyribonucleotides by ...
Biology Products: